Compare WST & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WST | INSM |
|---|---|---|
| Founded | 1923 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.6B | 22.4B |
| IPO Year | 2004 | 2000 |
| Metric | WST | INSM |
|---|---|---|
| Price | $346.61 | $128.32 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 24 |
| Target Price | ★ $325.86 | $201.17 |
| AVG Volume (30 Days) | 640.3K | ★ 3.1M |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.30% | N/A |
| EPS Growth | ★ 1.49 | N/A |
| EPS | ★ 4.07 | N/A |
| Revenue | ★ $2,886,900,000.00 | N/A |
| Revenue This Year | $6.76 | $182.31 |
| Revenue Next Year | $6.22 | $65.19 |
| P/E Ratio | $85.87 | ★ N/A |
| Revenue Growth | ★ 1.95 | N/A |
| 52 Week Low | $223.83 | $90.39 |
| 52 Week High | $386.00 | $212.75 |
| Indicator | WST | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 52.99 | 62.28 |
| Support Level | $349.41 | $95.24 |
| Resistance Level | $358.67 | $140.30 |
| Average True Range (ATR) | 6.59 | 4.89 |
| MACD | -0.03 | 1.80 |
| Stochastic Oscillator | 70.98 | 74.10 |
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.